Knowing a tumor's molecular type enables neurosurgeons to make decisions such as how much brain tissue to remove and whether to place tumor-killing drugs directly into the brain - while the patient is still on the operating table.
The study by researchers at New York University, Columbia Engineering, and the New York Genome Center, combines a deep learning model with CRISPR screens to control the expression of human genes in different ways - such as flicking a light switch to shut them off completely or by using a dimmer knob to partially turn down their activity.